Dr. Ahn on Targeted Therapies in Gastric/Gastroesophageal Cancers

Daniel H. Ahn, DO
Published: Thursday, May 24, 2018



Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric and esophageal cancers.

In terms of targeted therapies, Ahn states that there are 3 relevant targets right now, including VEGF. There are positive data looking at using ramucirumab (Cyramza) in the refractory setting. However, the positive data from the RAINFALL study did not manifest in clinical significance. The difference was about 0.3 months. Therefore, Ahn recommends that ramucirumab be avoided in the frontline setting and only considered in the second-line setting or beyond.

Other agents that target VEGF include regorafenib (Stivarga) and apatinib. Both agents are oral, tyrosine kinase inhibitors (TKIs). Regorafenib is a multitargeted oral TKI, as well as apatinib—which is a selective VEGFR2 TKI. Both agents are currently being investigated in ongoing phase III trials, states Ahn.


Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric and esophageal cancers.

In terms of targeted therapies, Ahn states that there are 3 relevant targets right now, including VEGF. There are positive data looking at using ramucirumab (Cyramza) in the refractory setting. However, the positive data from the RAINFALL study did not manifest in clinical significance. The difference was about 0.3 months. Therefore, Ahn recommends that ramucirumab be avoided in the frontline setting and only considered in the second-line setting or beyond.

Other agents that target VEGF include regorafenib (Stivarga) and apatinib. Both agents are oral, tyrosine kinase inhibitors (TKIs). Regorafenib is a multitargeted oral TKI, as well as apatinib—which is a selective VEGFR2 TKI. Both agents are currently being investigated in ongoing phase III trials, states Ahn.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Publication Bottom Border
Border Publication
x